Fibrolamellar hepatocellular carcinoma: current clinical perspectives

Clicks: 203
ID: 6653
2015
Fibrolamellar hepatocellular carcinoma: current clinical perspectives Kelly J Lafaro,1 Timothy M Pawlik2 1Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, 2Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Fibrolamellar carcinoma (FLC) is a variant of hepatocellular carcinoma (HCC), which comprises ~1%–9% of all HCCs. Although FLC is a variant of HCC, it is distinct from HCC in that it most often affects younger patients (10–35 years of age) with no underlying liver disease. FLC often presents with vague abdominal pain, nausea, abdominal fullness, malaise, and weight loss. Surgery is the current mainstay of treatment for FLC and remains the only potentially curative option. While FLCs are considered less responsive to chemotherapy than their classic HCC counterparts, there have been suggestions that multimodality treatments may be effective, especially in advanced cases. Further research is necessary to determine effective systemic therapies as an adjunct to surgery for FLC. Keywords: hepatocellular carcinoma, fibrolamellar, hepatocyte paraffin I, locoregional therapy
Reference Key
kelly2015fibrolamellarjournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kelly J Lafaro;Timothy M Pawlik and
Journal journal of hepatocellular carcinoma
Year 2015
DOI 10.2147/JHC.S75153
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.